From Patient to Advocate: 30 Years Since My Diagnosis with Amyloidosis
Thirty years ago, 1995, was the biggest year of my life. I completed my master’s in architecture. I met and married my husband. And I was diagnosed with amyloidosis. The word was foreign to me. I had never heard of it, but suddenly it was the defining word of my future. For nearly a decade ...
ATTR Amyloidosis MAGNITUDE Clinical Trials Temporarily on Hold
There has been an important update regarding the MAGNITUDE (NCT06128629) and MAGNITUDE-2 (NCT06672237) clinical trials evaluating nexiguran ziclumeran (nex-z, also known as NTLA-2001) for transthyretin (ATTR) amyloidosis. Nex-z is an experimental (not yet approved) gene-editing treatment being developed for people...
The Double-Drug Dilemma: Should We Combine Treatments in ATTR-CM Amyloidosis?
For many living with ATTR amyloidosis, recent advances have brought hope. In just seven years we have gone from no approved treatments to having a number of options. Stabilizers, silencers, and broader awareness leading to earlier diagnoses have all marked important progress. Yet as...
On a medical mission in Guatemala, Alison was working 16-to-18-hour days on cement floors, with little relief from the heat or time to rest. Her legs began to swell, but given the grueling schedule and harsh conditions, she assumed it...
Phase 3 Clinical Trial of Anselamimab in AL Amyloidosis Fails to Meet Primary Endpoint
BREAKING NEWS: Alexion, AstraZeneca Rare Disease, has announced that the Phase 3 CARES clinical trial did not meet its main goal. Anselamimab did not show a statistically significant improvement in survival during the study period. The goal of the CARES...
Join our email list to stay up to date on the latest Amyloidosis news.
Learn more about the importance of imaging from nationally known amyloidosis expert, Dr. Ahmad Masri. A heart specialist and leader of OHSU’s Cardiac Amyloidosis and Hypertrophic Cardiomyopathy programs, Dr. Masri discussed how imaging plays a key role in identifying amyloidosis and monitoring treatment.